{"id":1448987,"date":"2024-01-07T19:00:00","date_gmt":"2024-01-08T00:00:00","guid":{"rendered":"https:\/\/bugaluu.com\/news\/?p=1448987"},"modified":"2024-01-07T19:00:00","modified_gmt":"2024-01-08T00:00:00","slug":"paxlovid-does-not-reduce-risk-of-long-covid-potentially-linked-to-rebound-symptoms-study","status":"publish","type":"post","link":"https:\/\/bugaluu.com\/news\/paxlovid-does-not-reduce-risk-of-long-covid-potentially-linked-to-rebound-symptoms-study\/1448987\/","title":{"rendered":"Paxlovid Does Not Reduce Risk Of Long COVID, Potentially Linked To Rebound Symptoms: Study"},"content":{"rendered":"

Paxlovid Does Not Reduce Risk Of Long COVID, Potentially Linked To Rebound Symptoms: Study<\/span><\/p>\n

\n

Authored by Amie Dahnke via The Epoch Times<\/a> (Emphasis ours),<\/em><\/p>\n

(Wolfgang Rattay\/Reuters\/Illustration)<\/em><\/a><\/p>\n

Paxlovid, an antiviral medication prescribed to treat symptoms associated with COVID-19, does not reduce the risk of developing long COVID in vaccinated people recovering at home.<\/strong><\/p>\n

The report comes from a new study published in the Journal of Medical Virology<\/a> on Thursday. Conducted by a team of researchers from the University of California\u2013San Francisco, the study also found that more people are experiencing rebounds of their COVID symptoms after taking Paxlovid (nirmatrelvir-ritonavir) than previously reported.<\/p>\n

Paxlovid is the first antiviral pill approved by the U.S. Food and Drug Administration (FDA) to treat mild and moderate COVID-19 in adults.<\/strong> It is typically prescribed to those at high risk of having the virus progress to a severe illness, including hospitalization or death. The medication has also been authorized for use in children 12 and older who are at risk of severe outcomes from COVID-19.<\/p>\n

According to manufacturer Pfizer, initial trials<\/a> of Paxlovid showed it reduced hospitalizations and death in unvaccinated COVID patients by 86 percent to 89 percent. A real-world study conducted by the U.S. Centers for Disease Control and Prevention (CDC) showed that adults who took Paxlovid within the first five days of a COVID-19 diagnosis had a 51 percent lower hospitalization rate within 30 days than those who did not take the medication. More recent studies have indicated lower efficacy rates, with patients having about 37 percent<\/a> reduced hospitalization and death risk.<\/p>\n

\n

However, no study has pointed to whether the drug helps protect people from getting long COVID, noted authors of the UC San Francisco study.<\/p>\n

Paxlovid Did Not Prevent Long COVID<\/h2>\n

To determine if Paxlovid protects against long COVID, the research team examined over 4,600 vaccinated individuals from the UC San Fransisco COVID-19 Citizen Science study who experienced their first positive COVID-19 tests between March and August 2022. None of the patients was hospitalized. About 20 percent of patients took the three-pill course of Paxlovid, while about 80 percent did not.<\/p>\n<\/div>\n

In December 2022, the patients answered a follow-up survey that included questions about long COVID, COVID rebound symptoms, and how long they continued to test positive.<\/p>\n

\u201cWe found a higher proportion with clinical rebound than previously reported, but did not identify an effect of posttreatment rebound on Long COVID symptoms<\/strong>,\u201d researchers wrote.<\/p>\n

\n

The team found little difference between the two groups. For example, roughly 16 percent of patients prescribed Paxlovid had long-COVID symptoms compared to about 14 percent who were not prescribed the medication. Long-COVID patients in each group experienced fatigue, shortness of breath, confusion, headache, and changes in sense of smell and taste.<\/p>\n

Paxlovid Rebound Symptoms Confirmed<\/h2>\n

The UC San Francisco study reported that just over 1 in 5 individuals (21 percent) who reported getting better after taking Paxlovid experienced rebound symptoms, or a return of their COVID symptoms. Among those who experienced rebounds, 10.8 percent reported one or more long-COVID symptoms.<\/p>\n<\/div>\n

Additionally, retesting positive was common among rebound patients; 25.7 percent of individuals who took Paxlovid and repeated antigen testing after testing negative ended up testing positive.<\/p>\n

In all, just over 26 percent of participants reported either rebound symptoms or test positivity,<\/strong> the study noted.<\/p>\n

Of the roughly 75 percent who didn\u2019t experience rebound while on Paxlovid, 8.3 percent reported at least one long-COVID symptom.<\/p>\n

The study echoes a Nov. 13, 2023, study<\/a> conducted by Harvard Medical School (HMS) researchers also indicating that 1 in 5 individuals who took Paxlovid experienced a rebound of symptoms.<\/p>\n

\u201cWe conducted this study to address lingering questions about Paxlovid and virologic rebound in COVID-19 treatment,\u201d senior author Dr. Mark Siedner, associate professor of medicine at HMS and an infectious disease clinician and researcher at Massachusetts General Hospital, said in a HMS press release. \u201cWe found that the virologic rebound phenomenon was much more common than expected\u2014in over 20 percent of people taking Paxlovid\u2014and that individuals shed live virus when experiencing a rebound, which means they may be contagious after initial recovery.\u201d<\/p>\n

Previous clinical trials suggested that between 1 percent and 2 percent of patients who took Paxlovid experienced rebound, according to the press release.<\/p>\n<\/div>\n

Tyler Durden<\/a><\/span>
\nSun, 01\/07\/2024 – 14:00<\/span><\/p>\n

\u200bhttps:\/\/www.zerohedge.com\/political\/paxlovid-does-not-reduce-risk-long-covid-potentially-linked-rebound-symptoms-study<\/a>\u00a0<\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"

Paxlovid Does Not Reduce Risk Of Long COVID, Potentially Linked To Rebound Symptoms: Study Authored by Amie Dahnke via The Epoch Times (Emphasis ours), (Wolfgang…<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1448987","post","type-post","status-publish","format-standard","hentry","category-news","wpcat-1-id"],"_links":{"self":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts\/1448987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/comments?post=1448987"}],"version-history":[{"count":0,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts\/1448987\/revisions"}],"wp:attachment":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/media?parent=1448987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/categories?post=1448987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/tags?post=1448987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}